Cystic Fibrosis Foundation issued the following clinical trial alerts in January:
January 10, 2022
BALANCE-CF 1: Study of BI 1265162, a mucus clearance drug, in teens and adults with CF
Status: Completed with results
Description: This study evaluated the safety and effectiveness of BI 1265162, a drug intended to improve the clearance of mucus from the lungs.
Age: 12 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: 40 to 90%
Number of Visits: 5
Length of Participation: 7 weeks
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT04059094
Phase 2 study of riociguat in adults with CF
Status: Completed with results
Description: This study evaluated the safety, tolerability, and effectiveness of the oral drug riociguat in adults with CF who have two copies of the F508del mutation and were not receiving CFTR modulator therapy.
Age: 18 Years and Older
Mutation: Two Copies F508del
Fev1% Predicted: 60 to 90%
Number of Visits: 9
Length of Participation: 28 days
ClinicalTrials.gov link: https://www.clinicaltrials.gov/ct2/show/NCT02170025
January 28, 2022
STOP 2: Treatment of pulmonary exacerbations in people with CF
Status: Complete with reults
Description: This study evaluated the safety and effectiveness of different lengths of intravenous (IV) treatment for pulmonary exacerbations in people with CF.
Age: 18 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: No FEV1 Limit
Number of Visits: 3
Length of Participation: 35 days
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT02781610